Press for TearScience
TearScience, Inc., a privately-held medical device company, today announced that it has received U.S. Food and Drug Administration (FDA) clearance for its next generation product of its LipiFlow® Thermal Pulsation System , a medical device that treats evaporative dry eye by liquefying and evacuating obstructions in meibomian glands located in the eyelids. The second generation product includes a more robust graphical user interface and provides the ability for physicians to treat both of a patient’s eyes simultaneously.
In October 2011, the 6-year-old privately held Morrisville medical device company announced a $15 million venture debt deal with Oxford Finance and Silicon Valley Bank. That was on top of a year-earlier $44.5 million in award-winning Series C funding.
TearScience, Inc., a venture funded medical device company, announced it has been granted several patents on its LipiView Ocular Surface Interferometer medical device. The LipiView allows eye care physicians to assess the tear film of dry eye patients.
TearScience, Inc., a privately-held medical device company, today announced Toronto-based Herzig Eye Institute, one of the leading authorities in laser vision correction and advanced cataract and refractive surgery, as its first Center of Excellence.